tiprankstipranks
Candel Therapeutics, Inc. (CADL)
NASDAQ:CADL
US Market
CADL
Candel Therapeutics
RESEARCH TOOLSreports

Candel Therapeutics (CADL) Stock News & Sentiment

440 Followers
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
Premium
Ratings
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
27d ago
CADL
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
Premium
Ratings
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
1M ago
CADL
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
Premium
Company Announcements
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
1M ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
Premium
Ratings
Candel Therapeutics: Advancing CAN-2409 Toward a 2026 BLA on Strengthening Prostate Cancer Data and Solid Cash Runway
1M ago
CADL
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
Premium
Ratings
Candel Therapeutics: Advancing CAN-2409 Toward BLA With Platform-Like Oncology Potential and Diversified Pipeline Upside
1M ago
CADL
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
Premium
Company Announcements
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
2M ago
8K
CADL
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
Premium
Company Announcements
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
2M ago
8K
CADL
More CADL News >

CADL News on the Web

Candel Therapeutics price target raised to $26 from $22 at Citi
TipRanks News
Bullish
CAN-2409’s Emerging Survival Benefit and Biomarker-Driven Immunotherapy Platform Support Buy Rating and $23 Target
TipRanks News
Bullish
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
Proactive Investors
Bullish
Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC
TipRanks News
Bullish
Candel Therapeutics Reports Extended Survival in NSCLC: 50% of Patients Survive Over 24 Months with CAN-2409 After Immune Checkpoint Failure
Market Chameleon
Neutral
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Health Catalyst (HCAT) and Candel Therapeutics (CADL)
TipRanks News
Neutral
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CADL’s Media Buzz Sentiment?
Currently, no data Available
What is CADL’s weekly average amount of articles?
Currently, no data Available
What is CADL’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
AORTArtivion
STAAStaar Surgical
IVVDInvivyd
SLPSimulations Plus
REPLReplimune Group
Showing the stocks with the most bullish news sentiment over the past week